Corvus Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Corvus Pharmaceuticals, Inc.‘s stocks are currently a part of 19 hedge funds’ portfolios, which represents 8.95% of the total amount of its stocks outstanding. This makes up a total of 4.16M shares of Corvus Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -80.51% or -17.20M shares fewer. As for the holding position changes, 21.05% (4) of current hedge fund investors increased the number of shares held, 15.79% (3) of current holders sold a part of the shares held, and 21.05% (4) closed the holdings completely. 1 hedge funds are new holders of Corvus Pharmaceuticals, Inc. stock in Q1 2023, it is 5.26% of total holders.
Hedge funds holding Corvus Pharmaceuticals (Q2 2018 – Q1 2023)
| Q2 2018 | 56 |
|---|---|
| Q3 2018 | 60 |
| Q4 2018 | 60 |
| Q1 2019 | 58 |
| Q2 2019 | 43 |
| Q3 2019 | 34 |
| Q4 2019 | 35 |
| Q1 2020 | 37 |
| Q2 2020 | 36 |
| Q3 2020 | 33 |
| Q4 2020 | 35 |
| Q1 2021 | 48 |
| Q2 2021 | 44 |
| Q3 2021 | 56 |
| Q4 2021 | 59 |
| Q1 2022 | 54 |
| Q2 2022 | 41 |
| Q3 2022 | 39 |
| Q4 2022 | 40 |
| Q1 2023 | 19 |
Hedge funds changes in Corvus Pharmaceuticals positions (Q2 2018 – Q1 2023)
| Q2 2018 | 8 | 28 | 12 | 6 | 2 |
|---|---|---|---|---|---|
| Q3 2018 | 9 | 24 | 14 | 5 | 8 |
| Q4 2018 | 8 | 23 | 15 | 8 | 6 |
| Q1 2019 | 4 | 18 | 23 | 6 | 7 |
| Q2 2019 | 5 | 14 | 15 | 18 | -9 |
| Q3 2019 | 3 | 14 | 10 | 11 | -4 |
| Q4 2019 | 7 | 8 | 14 | 6 | 0 |
| Q1 2020 | 9 | 10 | 9 | 6 | 3 |
| Q2 2020 | 6 | 8 | 8 | 6 | 8 |
| Q3 2020 | 5 | 10 | 11 | 8 | -1 |
| Q4 2020 | 8 | 5 | 13 | 5 | 4 |
| Q1 2021 | 21 | 14 | 8 | 8 | -3 |
| Q2 2021 | 3 | 12 | 14 | 7 | 8 |
| Q3 2021 | 23 | 9 | 15 | 11 | -2 |
| Q4 2021 | 18 | 18 | 12 | 15 | -4 |
| Q1 2022 | 7 | 14 | 17 | 12 | 4 |
| Q2 2022 | 2 | 13 | 8 | 14 | 4 |
| Q3 2022 | 3 | 8 | 9 | 6 | 13 |
| Q4 2022 | 8 | 6 | 12 | 7 | 7 |
| Q1 2023 | 1 | 4 | 3 | 4 | 7 |
Hedge funds changes in Corvus Pharmaceuticals stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 0 | 0 |
|---|---|---|
| Q3 2018 | 0 | 0 |
| Q4 2018 | 0 | 0 |
| Q1 2019 | 0 | 0 |
| Q2 2019 | 0 | 0 |
| Q3 2019 | 0 | 0 |
| Q4 2019 | 16,000 | 0 |
| Q1 2020 | 0 | 0 |
| Q2 2020 | 0 | 0 |
| Q3 2020 | 204,000 | 13,000 |
| Q4 2020 | 361,000 | 144,000 |
| Q1 2021 | 93,000 | 462,000 |
| Q2 2021 | 104,000 | 261,000 |
| Q3 2021 | 7,175,000 | 2,800,000 |
| Q4 2021 | 552,000 | 536,000 |
| Q1 2022 | 174,000 | 337,000 |
| Q2 2022 | 80,000 | 60,000 |
| Q3 2022 | 40,000 | 30,000 |
| Q4 2022 | 22,515 | 30,935 |
| Q1 2023 | 455,000 | 1,000 |